Tag: BMC

  • Identification of alternative topics to diversify medicine, dentistry, and pharmacy student theses: a mixed method study | BMC Medical Education

    Identification of alternative topics to diversify medicine, dentistry, and pharmacy student theses: a mixed method study | BMC Medical Education

    Study design

    Thinking of the multidimensional mother nature of the medical science theses, which generally offer with elaborate human functions, they can’t be dealt with from an exclusively technological point of view as a result, a mixed-strategy analyze with an exploratory sequential style was selected. In the exploratory sequential approach, first, the researcher starts with a qualitative study period and explores the sights of contributors. Then the facts are analyzed, and the facts is used in a 2nd, quantitative period. The qualitative stage might be utilised to establish an instrument that most effective fits the sample underneath examine [17].

    Location

    The review was executed in the Education Growth Center of Kerman College of Medical Science. The qualitative component of the research was executed from February to April 2021. The quantitative ingredient was performed from April to June 2021.

    Literature research

    We performed non-systematic literature queries on Medline, EMBASE, Net of Science, ERIC, and Scopus with the keywords and phrases “thesis”, “alternative”, “student”, “medicine”, “dentistry”, “pharmacy”, and “dissertation” followed by extra lookups of the reference lists of related content articles. We utilized this literature to (i) notify the layout of this research, (ii) structure the pointers for the target group assembly and the questionnaire, and, most importantly, (iii) recognize the achievable alternate subject areas that may well also be researched in other configurations.

    Qualitative sampling and recruitment

    For the qualitative component, we used purposive sampling. The emphasis was on ‘purposively picking information and facts-rich’ situations [18]. The key inclusion criteria for the members in the focus team were: (i) college users with the working experience of academic functions in faculties of medication, dentistry, and pharmacy, (ii) faculty users with the working experience of supervising drugs, dentistry, and pharmacy scholar theses, and (iii) students fascinated in taking part in the university’s academic development affairs from faculties of medicine, dentistry, and pharmacy. Individuals provided 16 school customers and 4 pupils. They were invited by e-mail, and then invites have been verified in individual.

    Qualitative details collection

    The target team assembly lasted 90 minutes. In the beginning of the assembly, we gave contributors a temporary description of the benefits of the literature critique. Then participants were being requested the typical query, “What option subjects can be applied to diversify drugs, dentistry, and pharmacy student theses?” and ongoing with precise queries based on the discussion. With the guidance of the facilitator, participants reviewed the option subjects, resolved issues of clarity, and combined associated alternative subjects into a solitary item and clarification was delivered. In circumstance of disagreement, the human being who proposed the alternative subject areas could come to a decision whether or not or not to incorporate it with yet another product. Equivalent alternate matters were grouped via group dialogue and a label was chosen for every area. The facilitator (SN) tried using to engage all individuals in the dialogue and gave every person the possibility to remark, explain, and interpret their viewpoints. All the conversations have been recorded, and notes were being taken from the discussions and stated details.

    Qualitative info assessment

    The qualitative data ended up analyzed using the conventional written content analysis system, which works by using inductive content material investigation [19]. The transcript was reviewed a number of occasions for much better comprehending and general comprehension. Then, the transcript was divided into meaning models. The this means units were coded, and models in the same way coded were being interpreted for a shared indicating. MS analyzed the concentrate team text and drafted the manuscript. SN and RM carried out a individual examination of big sections of the text, and consensus was arrived at by way of discussion where by variations in assessment appeared.

    Quantitative sampling and recruitment

    The quantitative element included all the contributors of the aim team.

    Quantitative data collection

    Informed by the results of the qualitative study, we developed a questionnaire with 18 things to examine the extracted choice matters to diversify drugs, dentistry, and pharmacy scholar theses. This questionnaire evaluated each subject dependent on some standards, which include “leading to mastering research capabilities,” “leading to lifelong learning,” and “leading to studying proof-centered conclusion-making.” Products of the questionnaire ended up assessed applying a 5-place Likert scale ranging from strongly concur to strongly disagree, scored from 5 to 1, for statistical comparison.

    Information validity was examined by computing the content material validity ratio (CVR) and information validity index (CVI). The bare minimum acceptable CVR was .62 based on Lawshe’s desk. The formulation for calculating CVI in the Waltz and Bausell process is the amount of all the respondents in “relevancy,” “clarity,” and “simplicity” requirements divided by the number of authorities who gave a 3 or 4 score in the relevant query in that criterion. In this method, if an product has a score a lot more than .79, that item continues to be in the questionnaire. If CVI is among .70 and .79, the merchandise needs correction and revision and if it is a lot less than .70, the product is unacceptable, and it need to be omitted. Confront validity was explored by the expert’s opinions on the simplicity of thoughts and their fluency. Reliability evaluation was investigated by Cronbach’s alpha. Interior regularity larger than .7 was considered suitable.

    After investigating trustworthiness and validity, the last electronic variation of the questionnaire was sent to the individuals of the concentrate group. It was redistributed a person additional time at an about 2-7 days interval via E-mail and also followed up by social media.

    Quantitative details analysis

    We carried out a descriptive investigation applying SPSS edition 20.3 (i.e., mean price and normal deviation).

    Ethical approval

    The Investigation Ethics Committee of the Nationwide Agency for Strategic Study in Healthcare Education and learning accepted the analyze (No. IR.NASRME.REC.1400.038). The individuals did not get any incentives, and participation was voluntary. Verbal consent for participation was obtained based mostly on the proposal permitted by the Ethics Committee.

  • Ngan HYS, Seckl MJ, Berkowitz RS, Xiang Y, Golfier F, Sekharan PK, et al. Diagnosis and management of gestational trophoblastic disease: 2021 update. Int J Gynaecol Obstet. 2021;155(Suppl 1):86–93.

    Article 

    Google Scholar
     

  • Berkowitz RS, Goldstein DP. Chorionic tumors. N Engl J Med. 1996;335:1740–8.

    Article 

    Google Scholar
     

  • Ngan HY, Kohorn EI, Cole LA, Kurman RJ, Kim SJ, Lurain JR, et al. Trophoblastic disease. Int J Gynaecol Obstet. 2012;119(Suppl 2):130–6.

    Article 

    Google Scholar
     

  • Rice LW, Berkowitz RS, Lage JM, Goldstein DP, Bernstein MR. Persistent gestational trophoblastic tumor after partial hydatidiform mole. Gynecol Oncol. 1990;36:358–62.

    Article 

    Google Scholar
     

  • Feltmate CM, Growdon WB, Wolfberg AJ, Goldstein DP, Genest DR, Chinchilla ME, et al. Clinical characteristics of persistent gestational trophoblastic neoplasia after partial hydatidiform molar pregnancy. J Reprod Med. 2006;51:902–6.


    Google Scholar
     

  • Hancock BW, Nazir K, Everard JE. Persistent gestational trophoblastic neoplasia after partial hydatidiform mole: incidence and outcome. J Reprod Med. 2006;51:764–6.


    Google Scholar
     

  • Abu-Rustum NR, Yashar CM, Bean S, Bradley K, Campos SM, Chon HS, et al. Gestational trophoblastic neoplasia, version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Comper Canc Netw. 2019;17:1374–91.

    Article 

    Google Scholar
     

  • Goldstein DP, Berkowitz RS, Bernstein MR. Management of molar pregnancy. J Reprod Med. 1981;26:208–12.


    Google Scholar
     

  • Limpongsanurak S. Prophylactic actinomycin D for high-risk complete hydatidiform mole. J Reprod Med. 2001;46:110–6.


    Google Scholar
     

  • Uberti EM, Fajardo MC, Da Cunha AG, Ayub AC, Graudenz MS, Schmid H. Gestational trophoblastic neoplasia using prophylactic single bolus dose of actinomycin D in high-risk hydatidiform mole: a simple, effective, secure and low-cost approach without adverse effects on compliance to general follow-up or subsequent treatment. Gynecol Oncol. 2009;114:299–305.

    Article 

    Google Scholar
     

  • Lewis JL, Gore H, Hertig AT, Goss DA. Treatment of trophoblastic neoplasms. With rationale for the use of adjunctive chemotherapy at the time of indicated operation. Am J Obstet Gynecol. 1966;96:710–22.

    Article 

    Google Scholar
     

  • Wang Q, Fu J, Hu L, Fang F, Xie L, Chen H, et al. Prophylactic chemotherapy for hydatidiform mole to prevent gestational trophoblastic neoplasia. Cochrane Database Syst Rev. 2017;9:CD007289.


    Google Scholar
     

  • Goldstein DP, Berkowitz RS. Prophylactic chemotherapy of complete molar pregnancy. Semin Oncol. 1995;22:157–60.


    Google Scholar
     

  • Hancock BW. Difference in management and treatment: a critical appraisal. In: Hancock BW, Seckl MJ, Berkowitz RS, Cole LA, editors. Gestational trophoblastic disease. 3rd ed. London: Chapman & Hall Medical; 2009. p. 447–59.


    Google Scholar
     

  • Kim DS, Moon H, Kim KT, Moon YJ, Hwang YY. Effects of prophylactic chemotherapy for persistent trophoblastic disease in patients with complete hydatidiform mole. Obstet Gynecol. 1986;67:690–4.

    Article 

    Google Scholar
     

  • Seckl M. Time to stop offering prophylactic chemotherapy after molar pregnancies? BJOG. 2014;121:1420.


    Google Scholar
     

  • Soares PD, Maesta I, Costa OL, Charry RC, Dias A, Rudge MV. Geographical distribution and demographic characteristics of gestational trophoblastic disease. J Reprod Med. 2010;55:305–10.


    Google Scholar
     

  • Mangili G, Lorusso D, Brown J, Pfisterer J, Massuger L, Vaughan M, et al. Trophoblastic disease review for diagnosis and management: a joint report from the International Society for the Study of Trophoblastic Disease, European Organisation for the Treatment of Trophoblastic Disease, and the Gynecologic Cancer Inter Group. Int J Gynecol Cancer. 2014;24:S109-116.

    Article 

    Google Scholar
     

  • Charry RC. Presentation and management of molar pregnancy and gestational trophoblastic neoplasia in Latin America. In: Hancock BW, Seckl MJ, Berkowitz RS, Cole LA, editors. Gestational trophoblastic disease. 3rd ed. London: Chapman & Hall Medical; 2009. p. 407–19.


    Google Scholar
     

  • Xiang Y, Qi Z, Xiaohua W, Jihong L, Li L, Miqing Z, et al. Guidelines for the diagnosis and treatment of geatational trophoblastic disease (4th ed). Chin J Pract Gynecol Obstet. 2018;34:994–1001 (in Chinese).


    Google Scholar
     

  • Braga A, Moraes V, Maestá I, Amim Júnior J, Rezende-Filho Jd, Elias K, et al. Changing trends in the clinical presentation and management of complete hydatidiform mole among Brazilian women. Int J Gynecol Cancer. 2016;26:984–90.

    Article 

    Google Scholar
     

  • Lybol C, Sweep FC, Ottevanger PB, Massuger LF, Thomas CM. Linear regression of postevacuation serum human chorionic gonadotropin concentrations predicts postmolar gestational trophoblastic neoplasia. Int J Gynecol Cancer. 2013;23:1150–6.

    Article 

    Google Scholar
     

  • Kerkmeijer LG, Massuger LF, Ten Kate-Booij MJ, Sweep FC, Thomas CM. Earlier diagnosis and serum human chorionic gonadotropin regression in complete hydatidiform moles. Obstet Gynecol. 2009;113:326–31.

    Article 

    Google Scholar
     

  • Kaneki E, Kobayashi H, Hirakawa T, Matsuda T, Kato H, Wake N. Incidence of postmolar gestational trophoblastic disease in androgenetic moles and the morphological features associated with low risk postmolar gestational trophoblastic disease. Cancer Sci. 2010;101:1717–21.

    Article 

    Google Scholar
     

  • Ngan HYBH, Benedet JL, Jones H, Montruccoli GC, Pecorelli S, FIGO Committee on Gynecologic Oncology. Gestational trophoblastic neoplasia, FIGO 2000 staging and classification. Int J Gynecol Cancer. 2003;83(Suppl 1):175–7.

    Article 

    Google Scholar
     

  • Elias KM, Shoni M, Bernstein M, Goldstein DP, Berkowitz RS. Complete hydatidiform mole in women aged 40–49 years. J Reprod Med. 2012;57:254–8.


    Google Scholar
     

  • Kashimura Y, Kashmira M, Sugimori H, Tsukamoto N, Matsuyama T, Matsukuma K, et al. Prophylactic chemotherapy for hydatidiform mole: 5–15 years follow-up. Cancer. 1986;58:624–9.

    Article 

    Google Scholar
     

  • Park TK, Kim SN, Lee SK. Analysis of risk factors for postmolar trophoblastic disease: categorization of risk factors and effect of prophylactic chemotherapy. Yonsei Med J. 1966;37:412–9.

    Article 

    Google Scholar
     

  • Fasoli M, Ratti F, Francheschi S, La Vecchia C, Pecorelli S, Mangioni C. Management of gestational trophoblastic disease: results of a cooperative study. Obstet Gynecol. 1982;60:205–9.


    Google Scholar
     

  • Goldstein DP. Prevention of gestational trophoblastic disease by use of actinomycin D in molar pregnancies. Obstet Gynecol. 1974;43:475–9.


    Google Scholar
     

  • Goldstein DP. Prophylactic chemotherapy of patients with molar pregnancy. Obstet Gynecol. 1971;38:817–22.


    Google Scholar
     

  • Uberti EM, Diestel MC, Guimarães FE, De Nápoli G, Schmid H. Single-dose actinomycin D: efficacy in the prophylaxis of post molar gestational trophoblastic neoplasia in adolescents with high-risk hydatidiform mole. Gynecol Oncol. 2006;102:325–32.

    Article 

    Google Scholar
     

  • Fowler DJ, Lindsay I, Seckl MJ, Sebire NJ. Routine preevacuation ultrasound diagnosis of hydatidiform mole: experience of more than 1000 cases from a regional referral center. Ultrasound Obst Gyn. 2006;27:56–60.

    Article 

    Google Scholar
     

  • Koga K, Maeda K. Prophylactic chemotherapy with Amethopterin for prevention of choriocarcinoma following removal of hydatidiform mole. Am J Obstet Gynecol. 1968;100:270–5.

    Article 

    Google Scholar
     

  • Yamamoto E, Trinh TD, Sekiya Y, Tamakoshi K, Nguyen XP, Nishino K, et al. The management of hydatidiform mole using prophylactic chemotherapy and hysterectomy for high-risk patients decreased the incidence of gestational trophoblastic neoplasia in Vietnam: a retrospective observational study. Nagoya J Med Sci. 2020;82:183–91.


    Google Scholar
     

  • Evaluation the effects of red yeast rice in combination with statin on lipid profile and inflammatory indices; a randomized clinical trial | BMC Nutrition

    Evaluation the effects of red yeast rice in combination with statin on lipid profile and inflammatory indices; a randomized clinical trial | BMC Nutrition

    Supplied the detrimental effects of dyslipidemia and in light of sure restrictions to statin use, this randomized medical demo (RCT) sought to assess the outcomes of crimson yeast rice (RYR) in individuals with dyslipidemia currently on statin remedy. We identified that RYR, together with statin remedy, can appreciably lower complete cholesterol amounts devoid of adversely affecting liver enzymes concentrations (AST, ALT).

    Various meta-analyses have verified the potent romance among LDL degrees and the risk of cardiovascular illness (CVD) [18]. Just one meta-assessment by the Cholesterol Cure Trialists’ (CTT) Collaboration worked on data from 14 RCTs and about 90,000 topics. The examine instructed that as the serum level of LDL-C falls, the chance of CVD decreases accordingly [19]. A different CTT meta-investigation on a lot more than 170,000 patients discovered that just about every time the LDL concentration drops by one particular mmol/L, the chance of ischemic stroke, coronary artery disorder, and revascularization drops by over a single-fifth [20]. Simply because of the advantages of LDL-C reduction, lipid-lowering brokers – primarily statins – are extremely well known.

    Not long ago, RYR has acquired acceptance as an substitute LDL-decreasing agent with couple of adverse results [21]. Several meta-analyses have confirmed the outcome of RYR on the reduction of LDL-C. Just one the latest review worked on 20 RCTs and 6663 people it showed that after 2 months to 2 yrs of treatment, RYR diminished the serum LDL-C degree by 1.02 mmol/l (~ 39.4 mg/dl) (with 95{fe463f59fb70c5c01486843be1d66c13e664ed3ae921464fa884afebcc0ffe6c} self-confidence) in comparison with the placebo, indicating significant efficacy very similar to that of reduced-depth or small-dose statins (pravastatin 40 mg, simvastatin 10 mg, lovastatin 20 mg). The researchers also verified a slight boost in HDL-C and an insignificant lower in TG [14]. A different examine confirmed that clients acquiring RYR seasoned considerable decrements in serum LDL-C (23.{fe463f59fb70c5c01486843be1d66c13e664ed3ae921464fa884afebcc0ffe6c}) and whole cholesterol (15.5{fe463f59fb70c5c01486843be1d66c13e664ed3ae921464fa884afebcc0ffe6c}) levels relative to a command group next a sixteen-week treatment interval (P < 0.001) [22]. The lipid-lowering effect of RYR is believed to be due to the presence of monacolin K, which possesses the same structure as lovastatin [23]. It is thought that RYR limits the rate of hepatic cholesterol production by inhibiting the 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase enzyme [17].

    One consideration in the use of novel lipid-lowering agents is hepatotoxicity. A meta-analysis of seven trials [16, 24,25,26,27,28,29] assessed serum AST levels before and after intervention with RYR. The researchers showed that although the serum AST level were considerably higher in those who received RYR relative to controls, they remained within the normal range (0–40 U/L) [Total WMD = 1.55 (95{fe463f59fb70c5c01486843be1d66c13e664ed3ae921464fa884afebcc0ffe6c} CI: 0.26, 2.84) U/L, I2 = 0{fe463f59fb70c5c01486843be1d66c13e664ed3ae921464fa884afebcc0ffe6c}, P = 0.02, 7 trials (8 comparisons), n = 443]. Our study found that after 1 month of treatment, the serum AST level was only slightly higher in the intervention group than the placebo group (P = 0.074) and remained within the normal range. In the mentioned trials [16, 24,25,26,27,28,29], the serum ALT levels was significantly higher in the intervention group compared with the placebo group but again remained within the normal range (0–40 U/L) [Total WMD = 1.47 (95{fe463f59fb70c5c01486843be1d66c13e664ed3ae921464fa884afebcc0ffe6c} CI: 0.42, 2.51) U/L, I2 = 0{fe463f59fb70c5c01486843be1d66c13e664ed3ae921464fa884afebcc0ffe6c}, P = 0.006, 7 trials (8 comparisons), n = 443]. At the end of our study, the ALT level was also negligibly higher in the intervention group relative to the placebo group (P = 0.714) and remained within the normal range.

    Another important aspect related to RYR is that it may improve endothelial function. In one study, 50 coronary heart disease patients randomly received either RYR (1200 mg daily, containing 11.4 mg of monacolin K) or a placebo, and the serum hs-CRP concentration was monitored. After 6 weeks, those receiving RYR experienced reductions in hs-CRP (P < 0.001) [30]. However, in our study, changes in hs-CRP levels after 4 weeks of intervention were not significant compared with the placebo (P = 0.78).

    Although some recent studies only worked on the effect of RYR in isolation on LDL-C, our study investigated the effect of RYR when accompanied by another statin (atorvastatin or rosuvastatin) on both total cholesterol and LDL-C levels. Due to our limited sample size, further large-scale studies seem warranted. Another limitation was the significant differences in baseline total cholesterol and LDL levels between the study groups. Although the study was randomized, this may be due to the small sample size. We also measured the effect of RYR with only a one-month follow-up future studies should consider an extended period of follow-up.

    Limitations

    Although in this randomized trial, we showed that use of RYR is sfae with statin, this need further larger trials to show the effect of RYS on lipid profile.

  • The effect of prophylactic chemotherapy on treatment outcome of postmolar gestational trophoblastic neoplasia | BMC Women’s Health

    Allied health and complementary therapy usage in Australian women with chronic pelvic pain: a cross-sectional study | BMC Women’s Health

  • Daniels JP, Khan KS. Chronic pelvic pain in women. BMJ. 2010;341:c4834.

    Article 

    Google Scholar
     

  • Patnaik SS, Laganà AS, Vitale SG, Butticè S, Noventa M, Gizzo S, Valenti G, Rapisarda AMC, La Rosa VL, Magno C, et al. Etiology, pathophysiology and biomarkers of interstitial cystitis/painful bladder syndrome. Arch Gynecol Obstet. 2017;295(6):1341–59.

    CAS 
    Article 

    Google Scholar
     

  • Ahangari A. Prevalence of chronic pelvic pain among women: an updated review. Pain Physician. 2014;17(2):E141-147.

    Article 

    Google Scholar
     

  • EAU Guidelines on Chronic Pelvic Pain. https://uroweb.org/wp-content/uploads/EAU-Guidelines-on-Chronic-Pelvic-Pain-2020.pdf.

  • Rowlands IJ, Abbott JA, Montgomery GW, Hockey R, Rogers P, Mishra GD. Prevalence and incidence of endometriosis in Australian women: a data linkage cohort study. BJOG. 2021;128(4):657–65.

    CAS 
    Article 

    Google Scholar
     

  • Chapron C, Marcellin L, Borghese B, Santulli P. Rethinking mechanisms, diagnosis and management of endometriosis. Nat Rev Endocrinol. 2019;15(11):666–82.

    Article 

    Google Scholar
     

  • Armour M, Sinclair J, Ng CHM, Hyman MS, Lawson K, Smith CA, Abbott J. Endometriosis and chronic pelvic pain have similar impact on women, but time to diagnosis is decreasing: an Australian survey. Sci Rep. 2020;10(1):16253.

    CAS 
    Article 

    Google Scholar
     

  • Armour M, Lawson K, Wood A, Smith CA, Abbott J. The cost of illness and economic burden of endometriosis and chronic pelvic pain in Australia: a national online survey. PLoS ONE. 2019;14(10):e0223316.

    CAS 
    Article 

    Google Scholar
     

  • Armour M, Ciccia D, Stoikos C, Wardle J. Endometriosis and the workplace: lessons from Australia’s response to COVID-19. Aust N Z J Obstet Gynaecol. 2021. https://doi.org/10.1111/ajo.13458.

  • Laganà AS, Condemi I, Retto G, Muscatello MR, Bruno A, Zoccali RA, Triolo O, Cedro C. Analysis of psychopathological comorbidity behind the common symptoms and signs of endometriosis. Eur J Obstet Gynecol Reprod Biol. 2015;194:30–3.

    Article 

    Google Scholar
     

  • Laganà AS, La Rosa VL, Rapisarda AMC, Valenti G, Sapia F, Chiofalo B, Rossetti D, Ban Frangež H, Vrtačnik Bokal E, Vitale SG. Anxiety and depression in patients with endometriosis: impact and management challenges. Int J Womens Health. 2017;9:323–30.

    Article 

    Google Scholar
     

  • D’Alterio MN, Saponara S, Agus M, Laganà AS, Noventa M, Loi ES, Feki A, Angioni S. Medical and surgical interventions to improve the quality of life for endometriosis patients: a systematic review. Gynecol Surg. 2021;18(1):13.

    Article 

    Google Scholar
     

  • Rowe HJ, Hammarberg K, Dwyer S, Camilleri R, Fisher JRW. Improving clinical care for women with endometriosis: qualitative analysis of women’s and health professionals’ views. J Psychosom Obstet Gynecol. 2019;42:174–80.

    Article 

    Google Scholar
     

  • O’Hara R, Rowe H, Fisher J. Managing endometriosis: a cross-sectional survey of women in Australia. J Psychosom Obstet Gynaecol. 2020.
    https://doi.org/10.1080/0167482X.2020.1825374

  • Lukas I, Kohl-Schwartz A, Geraedts K, Rauchfuss M, Wölfler MM, Häberlin F, von Stephanie O, Eberhard M, Imthurn B, Imesch P, et al. Satisfaction with medical support in women with endometriosis. PLoS ONE. 2018;13(11):e0208023.

    Article 

    Google Scholar
     

  • Fisher C, Adams J, Hickman L, Sibbritt D. The use of complementary and alternative medicine by 7427 Australian women with cyclic perimenstrual pain and discomfort: a cross-sectional study. BMC Complement Altern Med. 2016;16:129.

    Article 

    Google Scholar
     

  • Chronic Disease Management (formerly Enhanced Primary Care or EPC). https://www1.health.gov.au/internet/main/publishing.nsf/Content/mbsprimarycare-chronicdiseasemanagement.

  • Armour M, Ferfolja T, Curry C, Hyman MS, Parry K, Chalmers KJ, Smith CA, MacMillan F, Holmes K. The prevalence and educational impact of pelvic and menstrual pain in Australia: A national online survey of 4202 young women aged 13–25 years. J Pediatr Adolesc Gynecol. 2020;33(5):511–8.

    Article 

    Google Scholar
     

  • National Statement on Ethical Conduct in Human Research 2007 (Updated 2018). www.nhmrc.gov.au/guidelines/publications/e72.

  • Simoens S, Hummelshoj L, Dunselman G, Brandes I, Dirksen C, D’Hooghe T, EndoCost C. Endometriosis cost assessment (the EndoCost study): a cost-of-illness study protocol. Gynecol Obstet Invest. 2011;71(3):170–6.

    Article 

    Google Scholar
     

  • 1249.0 – Australian Standard Classification of Cultural and Ethnic Groups (ASCCEG). http://www.abs.gov.au/ausstats/[email protected]/mf/1249.0.

  • Steel A, McIntyre E, Harnett J, Foley H, Adams J, Sibbritt D, Wardle J, Frawley J. Complementary medicine use in the Australian population: results of a nationally-representative cross-sectional survey. Sci Rep. 2018;8(1):17325.

    Article 

    Google Scholar
     

  • Pledger MJ, Cumming JN, Burnette M. Health service use amongst users of complementary and alternative medicine. N Z Med J. 2010;123(1312):26–35.

    PubMed 

    Google Scholar
     

  • Young K, Fisher J, Kirkman M. Women’s experiences of endometriosis: a systematic review and synthesis of qualitative research. J Fam Plan Reprod Health Care. 2015;41(3):225.

    Article 

    Google Scholar
     

  • Roomaney R, Kagee A. Coping strategies employed by women with endometriosis in a public health-care setting. J Health Psychol. 2015;21(10):2259–68.

    Article 

    Google Scholar
     

  • Grundström H, Kjølhede P, Berterö C, Alehagen S. “A challenge”—healthcare professionals’ experiences when meeting women with symptoms that might indicate endometriosis. Sex Reprod Healthc. 2016;7:65–9.

    Article 

    Google Scholar
     

  • Young K, Fisher J, Kirkman M. Clinicians’ perceptions of women’s experiences of endometriosis and of psychosocial care for endometriosis. Aust N Z J Obstet Gynaecol. 2017;57(1):87–92.

    Article 

    Google Scholar
     

  • Young K, Fisher J, Kirkman M. Women’s experiences of endometriosis: a systematic review and synthesis of qualitative research. J Fam Plan Reprod Health Care. 2015;41(3):225–34.

    Article 

    Google Scholar
     

  • Cant RP, Foster MM. Investing in big ideas: utilisation and cost of Medicare Allied Health services in Australia under the Chronic Disease Management initiative in primary care. Aust Health Rev. 2011;35(4):468–74.

    Article 

    Google Scholar
     

  • Fuentes-Márquez P, Cabrera-Martos I, Valenza MC. Physiotherapy interventions for patients with chronic pelvic pain: a systematic review of the literature. Physiother Theory Pract. 2019;35(12):1131–8.

    Article 

    Google Scholar
     

  • Lund I, Lundeberg T. Is acupuncture effective in the treatment of pain in endometriosis? J Pain Res. 2016;9:157–65.

    Article 

    Google Scholar
     

  • Hansen KE, Kesmodel US, Kold M, Forman A. Long-term effects of mindfulness-based psychological intervention for coping with pain in endometriosis: a six-year follow-up on a pilot study. Nordic Psychol. 2017;69(2):100–9.

    Article 

    Google Scholar
     

  • Huijs E, Nap A. The effects of nutrients on symptoms in women with endometriosis: a systematic review. Reprod Biomed Online. 2020;41(2):317–28.

    CAS 
    Article 

    Google Scholar
     

  • National Action Plan for Endometriosis. http://www.health.gov.au/internet/main/publishing.nsf/Content/endometriosis.

  • Facchin F, Barbara G, Saita E, Mosconi P, Roberto A, Fedele L, Vercellini P. Impact of endometriosis on quality of life and mental health: pelvic pain makes the difference. J Psychosom Obstet Gynecol. 2015;36(4):135–41.

    Article 

    Google Scholar
     

  • Di Donato N, Montanari G, Benfenati A, Monti G, Leonardi D, Bertoldo V, Facchini C, Raimondo D, Villa G, Seracchioli R. Sexual function in women undergoing surgery for deep infiltrating endometriosis: a comparison with healthy women. J Fam Plan Reprod Health Care. 2015;41(4):278–83.

    Article 

    Google Scholar
     

  • Cervigni M, Natale F. Gynecological disorders in bladder pain syndrome/interstitial cystitis patients. Int J Urol. 2014;21(Suppl 1):85–8.

    Article 

    Google Scholar
     

  • Tirlapur SA, Kuhrt K, Chaliha C, Ball E, Meads C, Khan KS. The “evil twin syndrome” in chronic pelvic pain: a systematic review of prevalence studies of bladder pain syndrome and endometriosis. Int J Surg. 2013;11(3):233–7.

    CAS 
    Article 

    Google Scholar
     

  • Spinks J, Hollingsworth B. Policy Implications of Complementary and Alternative Medicine Use in Australia: data from the National Health Survey. J Altern Complem Med. 2012;18(4):371–8.

    Article 

    Google Scholar
     

  • Reid R, Steel A, Wardle J, Trubody A, Adams J. Complementary medicine use by the Australian population: a critical mixed studies systematic review of utilisation, perceptions and factors associated with use. BMC Complem Altern Med. 2016;16(1):176.

    Article 

    Google Scholar
     

  • Schwartz ASK, Gross E, Geraedts K, Rauchfuss M, Wölfler MM, Häberlin F, von Orelli S, Eberhard M, Imesch P, Imthurn B, et al. The use of home remedies and complementary health approaches in endometriosis. Reprod Biomed Online. 2019;38(2):260–71.

    Article 

    Google Scholar
     

  • Chen L, Michalsen A. Management of chronic pain using complementary and integrative medicine. BMJ. 2017;357:j1284.

    Article 

    Google Scholar
     

  • Simoens S, Dunselman G, Dirksen C, Hummelshoj L, Bokor A, Brandes I, Brodszky V, Canis M, Colombo GL, DeLeire T, et al. The burden of endometriosis: costs and quality of life of women with endometriosis and treated in referral centres. Hum Reprod. 2012;27(5):1292–9.

    Article 

    Google Scholar
     

  • Shafrir AL, Wise LA, Palmer JR, Shuaib ZO, Katuska LM, Vinayak P, Kvaskoff M, Terry KL, Missmer SA. Validity of self-reported endometriosis: a comparison across four cohorts. Hum Reprod. 2021;36(5):1268–78.

    CAS 
    Article 

    Google Scholar
     

  • The effect of prophylactic chemotherapy on treatment outcome of postmolar gestational trophoblastic neoplasia | BMC Women’s Health

    Long term impact of the WHI studies on information-seeking and decision-making in menopause symptoms management: a longitudinal analysis of questions to a medicines call centre | BMC Women’s Health

  • 1.

    Nelson HD. Menopause. Lancet. 2008;371(9614):760–70.

    PubMed 
    Article 
    PubMed Central 

    Google Scholar
     

  • 2.

    Natari RB, Clavarino AM, McGuire TM, Dingle KD, Hollingworth SA. The bidirectional relationship between vasomotor symptoms and depression across the menopausal transition: a systematic review of longitudinal studies. Menopause. 2018;25(1):109–20.

    PubMed 
    Article 
    PubMed Central 

    Google Scholar
     

  • 3.

    Schbley BH. Socioeconomic factors in menopausal women’s use of hormone replacement therapy. J Women Aging. 2009;21(2):99–110.

    PubMed 
    Article 
    PubMed Central 

    Google Scholar
     

  • 4.

    Whiteley J, DiBonaventura M, Wagner JS, Alvir J, Shah S. The impact of menopausal symptoms on quality of life, productivity, and economic outcomes. J Womens Health. 2013;22(11):983–90.

    Article 

    Google Scholar
     

  • 5.

    Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288(3):321–33.

    Article 

    Google Scholar
     

  • 6.

    Committee TWHIS. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s health initiative randomized controlled trial. JAMA. 2004;291(14):1701–12.

    Article 

    Google Scholar
     

  • 7.

    Nabulsi AA, Folsom AR, White A, Patsch W, Heiss G, Wu KK, Szklo M. Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. N Engl J Med. 1993;328(15):1069–75.

    CAS 
    PubMed 
    Article 
    PubMed Central 

    Google Scholar
     

  • 8.

    Stoppe G, Dören M. Critical appraisal of effects of estrogen replacement therapy on symptoms of depressed mood. Arch Women Ment Health. 2002;5(2):39–47.

    CAS 
    Article 

    Google Scholar
     

  • 9.

    Brown S. Shock, terror and controversy: how the media reacted to the Women’s health initiative. Climacteric. 2012;15(3):275–80.

    CAS 
    PubMed 
    Article 
    PubMed Central 

    Google Scholar
     

  • 10.

    Lawton B, Rose S, McLeod D, Dowell A. Changes in use of hormone replacement therapy after the report from the Women’s Health Initiative: cross sectional survey of users. BMJ. 2003;327(7419):845.

    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • 11.

    Rossouw JE, Prentice RL, Manson JE, Wu L, Barad D, Barnabei VM, Ko M, LaCroix AZ, Margolis KL, Stefanick ML. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007;297(13):1465–77.

    CAS 
    PubMed 
    Article 
    PubMed Central 

    Google Scholar
     

  • 12.

    de Villiers TJ, Hall JE, Pinkerton JV, Cerdas Perez S, Rees M, Yang C, Pierroz DD. Revised global consensus statement on menopausal hormone therapy. Climacteric. 2016;19(4):313–5.

    PubMed 
    Article 
    PubMed Central 

    Google Scholar
     

  • 13.

    Wysowski DK, Governale LA. Use of menopausal hormones in the United States, 1992 through June, 2003. Pharmacoepidemiol Drug Saf. 2005;14(3):171–6.

    PubMed 
    Article 
    PubMed Central 

    Google Scholar
     

  • 14.

    Sarrel PM, Njike VY, Vinante V, Katz DL. The mortality toll of estrogen avoidance: an analysis of excess deaths among hysterectomized women aged 50 to 59 years. Am J Public Health. 2013;103(9):1583–8.

    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • 15.

    LaCroix AZ, Chlebowski RT, Manson JE, Aragaki AK, Johnson KC, Martin L, Margolis KL, Stefanick ML, Brzyski R, Curb JD, et al. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA. 2011;305(13):1305–14.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • 16.

    Bahri N, Pourali L, Esmaeeli H. Application of various menopausal symptoms treatment options and its related factors, Gonabad- 2016. Iran J Obstet Gynecol Infert. 2016;19(26):1–8.


    Google Scholar
     

  • 17.

    Drewe J, Bucher KA, Zahner C. A systematic review of non-hormonal treatments of vasomotor symptoms in climacteric and cancer patients. Springerplus. 2015;4(1):65.

    PubMed 
    PubMed Central 
    Article 
    CAS 

    Google Scholar
     

  • 18.

    Goldstein KM, Coeytaux RR, Williams JW Jr, Shepherd-Banigan M, Goode AP, McDuffie JR, Befus D, Adam S, Masilamani V, Van Noord MG. Non-pharmacologic treatments for menopause-associated vasomotor symptoms. Washington DC: DVA Health Services Research and Development Service; 2016.


    Google Scholar
     

  • 19.

    Carpenter JS, Byrne MM, Studts JL. Factors related to menopausal symptom management decisions. Maturitas. 2011;70(1):10–5.

    PubMed 
    Article 
    PubMed Central 

    Google Scholar
     

  • 20.

    Siyam T, Carbon J, Ross S, Yuksel N. Determinants of hormone therapy uptake and decision-making after bilateral oophorectomy (BO): a narrative review. Maturitas. 2019;120:68–76.

    PubMed 
    Article 
    PubMed Central 

    Google Scholar
     

  • 21.

    Hyde A, Nee J, Drennan J, Butler M, Howlett E. Hormone therapy and the medical encounter: a qualitative analysis of women’s experiences. Menopause. 2010;17(2):344–50.

    PubMed 
    Article 
    PubMed Central 

    Google Scholar
     

  • 22.

    Manson JE, Aragaki AK, Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Chlebowski RT, Howard BV, Thomson CA, Margolis KL, et al. Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the women’s health initiative randomized trials. JAMA. 2017;318(10):927–38.

    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • 23.

    Langer RD, Hodis HN, Lobo RA, Allison MA. Hormone replacement therapy—where are we now? Climacteric. 2021;24(1):3–10.

    CAS 
    PubMed 
    Article 
    PubMed Central 

    Google Scholar
     

  • 24.

    Thompson JJ, Ritenbaugh C, Nichter M. Why women choose compounded bioidentical hormone therapy: lessons from a qualitative study of menopausal decision-making. BMC Womens Health. 2017;17(1):97.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • 25.

    Velentzis LS, Banks E, Sitas F, Salagame U, Tan EH, Canfell K. Use of menopausal hormone therapy and bioidentical hormone therapy in Australian women 50 to 69 years of age: results from a national, cross-sectional study. PLoS ONE. 2016;11(3):e0146494.

    PubMed 
    PubMed Central 
    Article 
    CAS 

    Google Scholar
     

  • 26.

    Bahri N, Sajjadi M, Sadeghmoghadam L. The relationship between management strategies for menopausal symptoms and women’s decision making styles during menopausal transition. Prz Menopauzalny. 2019;18(3):174–9.

    PubMed 
    PubMed Central 

    Google Scholar
     

  • 27.

    Theroux R. Women’s decision making during the menopausal transition. J Am Acad Nurse Pract. 2010;22(11):612–21.

    PubMed 
    Article 
    PubMed Central 

    Google Scholar
     

  • 28.

    Zapata AML, Beaudreau SA, O’Hara R, Bereknyei Merrell S, Bruce J, Garrison-Diehn C, Gould CE. Information-seeking about anxiety and perceptions about technology to teach coping skills in older veterans. Clin Gerontol. 2017;41(8):346–56.

    PubMed 
    PubMed Central 

    Google Scholar
     

  • 29.

    Kingsberg SA, Schaffir J, Faught BM, Pinkerton JV, Parish SJ, Iglesia CB, Gudeman J, Krop J, Simon JA. Female sexual health: barriers to optimal outcomes and a roadmap for improved patient-clinician communications. J Women’s Health (2002). 2019;28(4):432–43.

    Article 

    Google Scholar
     

  • 30.

    Henwood F, Wyatt S, Hart A, Smith J. ‘Ignorance is bliss sometimes’: constraints on the emergence of the ‘informed patient’ in the changing landscapes of health information. Sociol Health Illn. 2003;25(6):589–607.

    PubMed 
    Article 
    PubMed Central 

    Google Scholar
     

  • 31.

    Pache DM, Hollingworth SA, van Driel ML, McGuire TM. Does consumer medicines interest reflect medicines use? An Australian observational study comparing medicines call center queries with medicines use. Res Social Adm Pharm. 2019;15(4):440–7.

    PubMed 
    Article 
    PubMed Central 

    Google Scholar
     

  • 32.

    Benchimol EI, Smeeth L, Guttmann A, Harron K, Moher D, Petersen I, Sørensen HT, von Elm E, Langan SM, Committee RW. The REporting of studies conducted using observational routinely-collected health data (RECORD) statement. PLoS Med. 2015;12(10):e1001885.

    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • 33.

    ATC/DDD Index 2017 https://www.whocc.no/atc_ddd_index/

  • 34.

    Commonwealth Department of Health and Aged Care, National Key Centre for Social Applications of Geographical Information Systems: Measuring remoteness: Accessibility/Remoteness Index of Australia (ARIA) revised edition: Commonwealth Department of Health and Aged Care; 2001.

  • 35.

    Australian Bureau of Statistics: Year book Australia 2012. Canberra: Australian Bureau of Statistics; 2012.

  • 36.

    Beasley TM, Schumacker RE. Multiple regression approach to analyzing contingency tables: Post hoc and planned comparison procedures. J Exp Educ. 1995;64(1):79–93.

    Article 

    Google Scholar
     

  • 37.

    Bazeley P. Analysing qualitative data: More than ‘identifying themes.’ Malays J Qual Res. 2009;2(2):6–22.


    Google Scholar
     

  • 38.

    Pines A, Sturdee DW, Birkhäuser MH, Schneider HPG, Gambacciani M, Panay N. IMS updated recommendations on postmenopausal hormone therapy. Climacteric. 2007;10(3):181–94.

    CAS 
    PubMed 
    Article 
    PubMed Central 

    Google Scholar
     

  • 39.

    Hengen KM, Alpers GW. What’s the risk? Fearful Individuals generally overestimate negative outcomes and they dread outcomes of specific events. Front Psychol. 2019;10:1676.

    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • 40.

    Loewenstein GF, Weber EU, Hsee CK, Welch N. Risk as feelings. Psychol Bull. 2001;127(2):267–86.

    CAS 
    PubMed 
    Article 
    PubMed Central 

    Google Scholar
     

  • 41.

    Shapiro M. Media and education of the consumer. Menopause. 2016;23(8):924–7.

    PubMed 
    Article 
    PubMed Central 

    Google Scholar
     

  • 42.

    Natari RB, McGuire TM, Baker PJ, Clavarino AM, Dingle KD, Hollingworth SA. Longitudinal impact of the Women’s health initiative study on hormone therapy use in Australia. Climacteric. 2019;22(5):489–97.

    CAS 
    PubMed 
    Article 
    PubMed Central 

    Google Scholar
     

  • 43.

    Crawford SL, Crandall CJ, Derby CA, El Khoudary SR, Waetjen LE, Fischer M, Joffe H. Menopausal hormone therapy trends before versus after 2002: impact of the Women’s health initiative study results. Menopause. 2018;26(6):588–97.

    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • 44.

    Ettinger B, Wang SM, Leslie RS, Patel BV, Boulware MJ, Mann ME, McBride M. Evolution of postmenopausal hormone therapy between 2002 and 2009. Menopause. 2018;25(11):1306–12.

    PubMed 
    Article 
    PubMed Central 

    Google Scholar
     

  • 45.

    Kloosterboer SM, McGuire T, Deckx L, Moses G, Verheij T, van Driel ML. Self-medication for cough and the common cold: Information needs of consumers. Aust Fam Physician. 2015;44(7):497–501.

    PubMed 
    PubMed Central 

    Google Scholar
     

  • 46.

    Gartoulla P, Davis S, Worsley R, Bell R. Use of complementary and alternative medicines for menopausal symptoms in Australian women aged 40–65 years. Med J Aust. 2015;203(3):146–146.

    PubMed 
    Article 
    PubMed Central 

    Google Scholar
     

  • 47.

    de Villiers TJ, Gass MLS, Haines CJ, Hall JE, Lobo RA, Pierroz DD, Rees M. Global Consensus Statement on menopausal hormone therapy. Maturitas. 2013;74(4):391–2.

    PubMed 
    Article 
    PubMed Central 

    Google Scholar
     

  • 48.

    Huston SA, Jackowski RM, Kirking DM. Women’s trust in and use of information sources in the treatment of menopausal symptoms. Womens Health Issues. 2009;19(2):144–53.

    PubMed 
    Article 
    PubMed Central 

    Google Scholar